PRODUCTS

Allegiance Bioscience is pursuing acquisitions and partnership opportunities for assets with the following characteristics:

• Predictable Revenue. Less than $50 million in annual sales and cash-flow positive.
• Specialized Focus.  Focus on smaller and niche Rx products that require limited promotional support, have a history of stable pricing and the potential for revenue growth via reinvigorated marketing, line extension or product enhancement (i.e., label expansion). Select OTC products that are derived from Rx products will also be considered excluding products that require mass marketing.
• Limited Development Risk.  Assets such as 505b(2) products that are in development will be considered if they are deemed to offer good commercial potential and fit Allegiance-Castleford’s acquisition criteria.  Assets that are pre-clinical, in early-stage development or represent a new chemical entity (NCE) will not be considered.
• Limited IP Risk. Preference for assets with limited patent expiration risk or those who have lost exclusivity but whose sales have stabilized.
• Ex-US Expansion. Potential for expansion via licensing or sales of rights.